Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clonally expanded CD38 hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor–associated arthritis
Runci Wang, Anvita Singaraju, Kathryne E. Marks, et al.
Science Immunology (2023) Vol. 8, Iss. 85
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Cytotoxic CD8+ T cells target citrullinated antigens in rheumatoid arthritis
Jae‐Seung Moon, Shady Younis, Nitya S. Ramadoss, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 41
Clinical and translational attributes of immune-related adverse events
Karijn P.M. Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, et al.
Nature Cancer (2024) Vol. 5, Iss. 4, pp. 557-571
Closed Access | Times Cited: 26
Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition
Nilasha Ghosh, Michael A. Postow, Chengsong Zhu, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 1, pp. e004008-e004008
Open Access | Times Cited: 37
High CD38 expression defines a mitochondrial function-adapted CD8+ T cell subset with implications for lung cancer immunotherapy
Lei-lei Lv, Jiawei Zhai, Jinrui Wu, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 2
Open Access
Protocol for assessing T cell receptor-mediated human T cell cytotoxicity
Kathryne E. Marks, Ifeoluwakiisi Adejoorin, John M. Sowerby, et al.
STAR Protocols (2025) Vol. 6, Iss. 1, pp. 103541-103541
Closed Access
Longitudinal Immune Cell Profiling in Patients With Early Systemic Lupus Erythematosus
Takanori Sasaki, Sabrina Bracero, Joshua Keegan, et al.
Arthritis & Rheumatology (2022) Vol. 74, Iss. 11, pp. 1808-1821
Open Access | Times Cited: 34
Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations
Kristian C. Williams, Abigail Gault, Amy E. Anderson, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy
Noha Abdel‐Wahab, María E. Suarez‐Almazor
Expert Review of Clinical Immunology (2024) Vol. 20, Iss. 8, pp. 873-893
Closed Access | Times Cited: 4
Single-cell analysis in rheumatic and allergic diseases: insights for clinical practice
Masayuki Nishide, Hiroshi Shimagami, Atsushi Kumanogoh
Nature reviews. Immunology (2024) Vol. 24, Iss. 11, pp. 781-797
Closed Access | Times Cited: 4
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study
P Petit, Douglas Daoudlarian, S. Latifyan, et al.
Annals of Oncology (2024)
Open Access | Times Cited: 3
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures
Chester Kao, Soren Charmsaz, Stephanie Alden, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 20
Open Access | Times Cited: 3
Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression
Jeffrey A. Sparks
Rheumatic Disease Clinics of North America (2024) Vol. 50, Iss. 2, pp. 147-159
Closed Access | Times Cited: 2
Comprehensive Co-Inhibitory Receptor (Co-IR) Expression on T Cells and Soluble Proteins in Rheumatoid Arthritis
Chin‐Man Wang, Yeong‐Jian Jan Wu, Liyu Huang, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 403-403
Open Access | Times Cited: 2
Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group
Nilasha Ghosh, Nina Couette, Wouter H. van Binsbergen, et al.
Seminars in Arthritis and Rheumatism (2022) Vol. 58, pp. 152110-152110
Open Access | Times Cited: 12
Clinical data mining: challenges, opportunities, and recommendations for translational applications
Huimin Qiao, Yijing Chen, Changshun Qian, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study
Abigail Gault, Linda Hogarth, Kristian C. Williams, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Distinct fibroblast functions associated with fibrotic and immune-mediated inflammatory diseases and their implications for therapeutic development
Alex Barron, Thomas Fabre, Saurav De
F1000Research (2024) Vol. 13, pp. 54-54
Open Access | Times Cited: 1
Rheumatic complications of checkpoint inhibitors: Lessons from autoimmunity
Gary Reynolds
Immunological Reviews (2023) Vol. 318, Iss. 1, pp. 51-60
Open Access | Times Cited: 4
Monitoring and Management of the Patient with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Current Perspectives
Karmela Kim Chan, Anne R. Bass
Journal of Inflammation Research (2022) Vol. Volume 15, pp. 3105-3118
Open Access | Times Cited: 8
Anticitrullinated peptide antibody epitope expansion and the HLA DRB1 ‘shared epitope’ are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis
Nilasha Ghosh, Pankti Reid, C. Aude, et al.
RMD Open (2023) Vol. 9, Iss. 2, pp. e003012-e003012
Open Access | Times Cited: 3
Associations between immune cell traits and autoimmune thyroid diseases: a bidirectional two-sample mendelian randomization study
ZheXu Cao, JiangSheng Huang, Xia Long
Immunogenetics (2024) Vol. 76, Iss. 4, pp. 219-231
Closed Access
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study
Pierre-Florent Petit, Douglas Daoudlarian, Sofiya Latifyan, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
The Roles of T cells in Immune Checkpoint Inhibitor-Induced Arthritis
Maike Chen, Huili Li, Baicheng Qu, et al.
Aging and Disease (2024)
Open Access
High CD38 expression defines a mitochondrial function adapted CD8 + T cell subset with implications for lung cancer immunotherapy
Lei-lei Lv, Jiawei Zhai, Jia-juan Wu, et al.
Research Square (Research Square) (2024)
Open Access
Opposing Regulation of TNF Responses and IL-1β+ Macrophages by PGE2-cAMP and IFN-γ Signaling
Upneet K. Sokhi, Bikash Mishra, Ruoxi Yuan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1 - Next Page

Scroll to top